Breaking News

The Almac Group Expands Facility

Doubling its Edinburgh Technopole facility to over 15,000 square feet for new laboratories and office space

The Almac Group is expanding its Edinburgh Technopole facility to allow scale-up of its personalized cancer vaccine activities.  Doubling its footprint in the Fleming Building to over 15,000 square feet, the company is investing in new laboratories and office space to meet growing demand for its services.  “Personalized cancer vaccines based on neo-antigenic peptides is an exciting new era for oncology, and our Technopole site already has the world’s first GMP-certified facility specifical...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters